Silence Therapeutics PLC SLNCF:OTCPK

*Data is delayed | Exchange | USD
Last | 12:20 PM EDT
8.00UNCH (UNCH)
Volume
625
52 week range
0.60 - 10.90
Loading...
  • Open8.00
  • Day High8.00
  • Day Low8.00
  • Prev Close8.00
  • 52 Week High10.90
  • 52 Week High Date03/20/24
  • 52 Week Low0.60
  • 52 Week Low Date08/29/23

Key Stats

  • Market Cap372.018M
  • Shares Out46.50M
  • 10 Day Average Volume722.25
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change433.33

KEY STATS

  • Open8.00
  • Day High8.00
  • Day Low8.00
  • Prev Close8.00
  • 52 Week High10.90
  • 52 Week High Date03/20/24
  • 52 Week Low0.60
  • 52 Week Low Date08/29/23
  • Market Cap372.018M
  • Shares Out46.50M
  • 10 Day Average Volume722.25
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change433.33

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-58.358M
  • ROE (TTM)-157.47%
  • Revenue (TTM)34.90M
  • Gross Margin (TTM)54.24%
  • Net Margin (TTM)-151.98%
  • Debt To Equity (MRQ)1.58%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Silence Therapeutics PLC

 

Content From Our Affiliates

Profile

MORE
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include...
Iain Ross
Non-Executive Chairman of the Board
Craig Tooman
President, Chief Executive Officer, Executive Director
Address
72 Hammersmith Road
London
W14 8TH
United Kingdom